Trinity Biotech

Trinity Biotech Gross Margin

The Gross Margin of Trinity Biotech (TRIB) as of Nov 11, 2026 is 38.57 %. In the previous year, Gross Margin was 34.83 % — a change of 10.72% (higher).

Gross Margin

38.57 %

YoY

10.72%

Last updated:

Gross Margin of Trinity Biotech is 2025 38.57 % . Gross Margin of Trinity Biotech was 2024 34.83 % . It decreases by 10.72% higher compared to the previous year.

For Trinity Biotech, the gross margin of 38.6% is down versus 41.2% a few years ago.

The Trinity Biotech Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
42.72 USD
Jan 1, 2019
42.15 USD
Jan 1, 2020
47.64 USD
Jan 1, 2021
41.23 USD
Jan 1, 2022
35.26 USD
Jan 1, 2023
34.22 USD
Jan 1, 2024
34.83 USD
Jan 1, 2025
38.57 USD
The Trinity Biotech Gross Margin history
YEARGross MarginYoY
38.57 %+10.72%
34.83 %+1.78%
34.22 %-2.95%
35.26 %-14.46%
41.23 %-13.46%
47.64 %+13.01%
42.15 %-1.32%
42.72 %+1.10%
42.25 %-2.33%
43.26 %-6.27%
46.15 %-3.86%
48.01 %+9,438.33%
0.50 %-1.71%
0.51 %-0.53%
0.51 %+5.01%
0.49 %+8.26%
0.45 %+1.55%
0.45 %+15.92%
0.38 %-10.10%
0.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Gross Margin of Trinity Biotech is 38.57 % in 2025.

Gross Margin of Trinity Biotech changed from 34.83 % to 38.57 %, representing a 10.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Trinity Biotech

All Key Metrics — Trinity Biotech